Fortress Biotech (FBIO) Stock Price, News & Analysis

Company Overview

Fortress Biotech, Inc. (NASDAQ: FBIO) is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiary companies and strategic partnerships. Its research and development activities have focused on areas including dermatology, immunology, oncology, rare diseases and other conditions with significant unmet medical needs.

The company’s portfolio has included dermatology products such as ZILXI, a topical minocycline foam for the treatment of inflammatory lesions associated with rosacea, and Qbrexza, a topical treatment for primary axillary hyperhidrosis. Fortress has also advanced clinical-stage therapies through affiliated companies, with development programs spanning specialty pharmaceuticals and targeted treatments.

Fortress was founded in 2014 and is headquartered in New York. Rather than operating as a single traditional drug manufacturer, the company uses an integrated model that combines internal drug development, subsidiary operations and licensing or commercialization partnerships. Its products and development programs are primarily directed toward the U.S. healthcare market, with selected opportunities for broader international commercialization.

Key Stats

• Today's Range: $1.86 to $1.94
• 50-Day Range: $1.87 to $2.93
• 52-Week Range: $1.83 to $4.53
• Volume: 198,151 shs
• Average Volume: 246,821 shs
• Market Capitalization: $64.37 million
• P/E Ratio: 0.73
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Hold

Fortress Biotech Stock Analysis - MarketRank™

Fortress Biotech scored higher than 70% of companies evaluated by MarketBeat, and ranked 245th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Fortress Biotech has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Fortress Biotech has a consensus price target of $17.00, representing about 780.8% upside from its current price of $1.93.

Amount of Analyst Coverage

Fortress Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Fortress Biotech is 0.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.49.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fortress Biotech is 0.73, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 38.45.

Price to Book Value per Share Ratio

Fortress Biotech has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.97% of the float of Fortress Biotech has been sold short.

Short Interest Ratio / Days to Cover

Fortress Biotech has a short interest ratio ("days to cover") of 16.09, which indicates bearish sentiment.

Change versus previous month

Short interest in Fortress Biotech has recently decreased by 7.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fortress Biotech does not currently pay a dividend.

Dividend Growth

Fortress Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Fortress Biotech has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

Search Interest

Only 3 people have searched for FBIO on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

1 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fortress Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.50% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/03/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:FBIO
• CIK: 1429260
• Web: www.fortressbiotech.com
• Phone: (781) 652-4500
• Fax: 781-652-4545
• Employees: 78
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Fortress Biotech: $17.00
• High Price Target: $17.00
• Low Price Target: $17.00
• Potential Upside/Downside: +780.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.64
• Trailing P/E Ratio: 0.73
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $6.82 million
• Net Margins: 163.32%
• Pretax Margin: 213.28%
• Return on Equity: 83.47%
• Return on Assets: 42.98%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 3.96
• Quick Ratio: 3.83

Sales & Book Value

• Annual Sales: $63.26 million
• Price / Sales: 1.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.00 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 33,350,000
• Free Float: 23,846,000
• Market Cap: $64.37 million
• Optionable: Optionable
• Beta: 1.25